Resultats de la cerca - Laurent Peyrin–Biroulet

Refinar resultats
  1. 1
    Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study

    Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study per Laurent Peyrin–Biroulet

    Publicat 2007
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Review article: remission rates achievable by current therapies for inflammatory bowel disease

    Review article: remission rates achievable by current therapies for inflammatory bowel disease per Laurent Peyrin‐Biroulet, Marc Lémann

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Histologic Features Predicting Postoperative Crohnʼs Disease Recurrence

    Histologic Features Predicting Postoperative Crohnʼs Disease Recurrence per Aude Bressenot, Laurent Peyrin–Biroulet

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases

    Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases per Aurélien Amiot, Laurent Peyrin–Biroulet

    Publicat 2014
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  5. 5
    Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise

    Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise per Silvio Danese, Laurent Peyrin–Biroulet

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  6. 6
    Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies

    Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies per Tine Jess, Christine Rungoe, Laurent Peyrin–Biroulet

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  7. 7
    Histologic Remission: The Ultimate Therapeutic Goal in Ulcerative Colitis?

    Histologic Remission: The Ultimate Therapeutic Goal in Ulcerative Colitis? per Laurent Peyrin‐Biroulet, Aude Bressenot, Wendy Kampman

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  8. 8
    Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review

    Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review per Laurent Peyrin–Biroulet, Nicolas Williet, P. Cacoub

    Publicat 2015
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  9. 9
    Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies

    Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies per Bénédicte Caron, Sailish Honap, Laurent Peyrin-Biroulet

    Publicat 2024
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  10. 10
    Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open‐label study

    Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open‐label study per Laurent Peyrin–Biroulet, Cécile Laclotte, Marc‐André Bigard

    Publicat 2007
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Systematic review and meta‐analysis: opportunistic infections and malignancies during treatment with anti‐integrin antibodies in inflammatory bowel disease

    Systematic review and meta‐analysis: opportunistic infections and malignancies during treatment with anti‐integrin antibodies in inflammatory bowel disease per Pavit Luthra, Laurent Peyrin–Biroulet, Alexander C. Ford

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  12. 12
    Review article: integrating budesonide‐MMX into treatment algorithms for mild‐to‐moderate ulcerative colitis

    Review article: integrating budesonide‐MMX into treatment algorithms for mild‐to‐moderate ulcerative colitis per Silvio Danese, Corey A. Siegel, Laurent Peyrin–Biroulet

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  13. 13
    Recent advances in cytokines: Therapeutic implications for inflammatory bowel diseases

    Recent advances in cytokines: Therapeutic implications for inflammatory bowel diseases per Guillaume Bouguen, Jean‐Baptiste Chevaux, Laurent Peyrin–Biroulet

    Publicat 2011
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  14. 14
    Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic

    Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic per Paulo Gustavo Kotze, Laurent Peyrin‐Biroulet, Silvio Danese

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  15. 15
    Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock

    Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock per Ferdinando D’Amico, Silvio Danese, Laurent Peyrin‐Biroulet

    Publicat 2020
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  16. 16
    Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm

    Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm per Ferdinando D’Amico, Laurent Peyrin–Biroulet, Silvio Danese

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  17. 17
    Can we change the natural course of inflammatory bowel disease?

    Can we change the natural course of inflammatory bowel disease? per Catherine Le Berre, Silvio Danese, Laurent Peyrin–Biroulet

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  18. 18
    Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey

    Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey per Ferdinando D’Amico, Laurent Peyrin–Biroulet, Silvio Danese

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    ARE WE READY FOR MULTIPLE SWITCHES BETWEEN REFERENCE PRODUCTS AND BIOSIMILARS?

    ARE WE READY FOR MULTIPLE SWITCHES BETWEEN REFERENCE PRODUCTS AND BIOSIMILARS? per Fábio Vieira Teixeira, Laurent Peyrin‐Biroulet, Silvio Danese

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  20. 20
    Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases

    Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases per Mariangela Allocca, Silvio Danese, Valérie Laurent, Laurent Peyrin–Biroulet

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:

Eines de cerca: